Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis

• Status: Unknown status
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

Orthotopic liver transplantation (OLT) is currently the most effective method for end-stage liver diseases. However, the critical shortage of donor organs, high cost, and the problem of immune rejection limit its clinical application, and even some patients on the waiting list will never survive to receive a matched liver. Stem cell transplantation instead of conventional medical therapy or orthotopic liver transplantation will be a promising alternate approach to regenerate damaged hepatic mass. Adult mesenchymal stem cells (MSCs) are generally thought of as an autologous source of regenerative cells in previous studies.In this study, the safety and efficacy of menstrual blood-derived stem cells transplantation for patients with liver cirrhosis will be evaluated.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: S-Evans Biosciences Co., Ltd.; S-Evans Biosciences Co.,Ltd.
• Collaborators: First Affiliated Hospital of Zhejiang University; Wuhan General Hospital of Guangzhou Military Command; Zhejiang General Hospital of Armed Police; Zhejiang University; Zhenjiang First People's Hospital
• Treatments: Interferons; Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

• Written informed consent

• Aged 20 to 50years

• Liver cirrhosis

• Negative pregnancy test

Exclusion Criteria:

• Pregnant or lactating women

• Malignancies

• Sepsis

• Vital organs failure

• Severe bacteria infection

• Vascular thromboses in the portal or hepatic veins